The National Drug Scheduling Advisory Committee and the national drug scheduling review process are funded on a cost-recovery basis.
For 2020, the cost of conducting a review of a submission is set at $44,870 (+HST). Payment in the full amount is required when the submission is forwarded to NAPRA.
There is a limit of two submissions reviewed at any given meeting. Please note: As of December 2014, the sharing of meeting costs will no longer be offered. Scheduling request sponsors are to pay the full amount for each submission.
For further information about the fee structure, please contact the Manager of Professional and Regulatory Affairs at 613-569-9658, ext. 230.